The Impact of Drug Interactions on the Results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes.

IF 1.9 4区医学 Q3 CLINICAL NEUROLOGY

Neurodegenerative Diseases Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI:10.1159/000540105

Isabelle Heewon Kang, Danny Bega

{"title":"The Impact of Drug Interactions on the Results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes.","authors":"Isabelle Heewon Kang, Danny Bega","doi":"10.1159/000540105","DOIUrl":null,"url":null,"abstract":"Introduction: DAT-SPECT imaging is approved as a diagnostic tool for the evaluation of suspected Parkinsonian syndromes, but the FDA-approved package insert lists 16 potential drugs that may interfere with the image obtained. The clinical impact of these drugs on imaging results has not been established. This study aimed to determine the accuracy of DAT-SPECT imaging in assessing presynaptic dopaminergic denervation in the setting of these drugs.Methods: This is a retrospective chart review of patients at a single center who underwent DAT-SPECT imaging while taking \"contraindicated\" drugs between December 2012 and December 2022.Results: A total of 1,224 charts were screened, and 153 (12.5%) charts met the inclusion criteria. Bupropion (32%, n = 49) and sertraline (26%, n = 40) were the most common contraindicated drugs. The false-positive rate was 9.2%.Conclusion: This retrospective analysis supports the concern that certain drugs may interfere with DAT-SPECT imaging results, leading to potential false positives. This has implications for how clinicians interpret DAT-SPECT imaging in patients taking these medications and whether they should advise patients to stop these medications before a scan is performed.","PeriodicalId":19115,"journal":{"name":"Neurodegenerative Diseases","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540105","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: DAT-SPECT imaging is approved as a diagnostic tool for the evaluation of suspected Parkinsonian syndromes, but the FDA-approved package insert lists 16 potential drugs that may interfere with the image obtained. The clinical impact of these drugs on imaging results has not been established. This study aimed to determine the accuracy of DAT-SPECT imaging in assessing presynaptic dopaminergic denervation in the setting of these drugs.

Methods: This is a retrospective chart review of patients at a single center who underwent DAT-SPECT imaging while taking "contraindicated" drugs between December 2012 and December 2022.

Results: A total of 1,224 charts were screened, and 153 (12.5%) charts met the inclusion criteria. Bupropion (32%, n = 49) and sertraline (26%, n = 40) were the most common contraindicated drugs. The false-positive rate was 9.2%.

Conclusion: This retrospective analysis supports the concern that certain drugs may interfere with DAT-SPECT imaging results, leading to potential false positives. This has implications for how clinicians interpret DAT-SPECT imaging in patients taking these medications and whether they should advise patients to stop these medications before a scan is performed.

查看原文本刊更多论文

药物相互作用对运动障碍专科DAT-SPECT成像结果的影响：对结果的回顾性分析

简介：DAT-SPECT 成像已被批准作为评估疑似帕金森综合征的诊断工具，但美国食品及药物管理局批准的包装说明书中列出了 16 种可能干扰成像的药物。这些药物对成像结果的临床影响尚未确定。本研究旨在确定在使用这些药物的情况下，DAT-SPECT 成像在评估突触前多巴胺能神经支配方面的准确性：这是一项回顾性病历审查，审查对象为2012年12月至2022年12月期间在一个中心服用 "禁忌 "药物并接受DAT-SPECT成像检查的患者：共筛选出 1224 份病历，其中 153 份（12.5%）符合纳入标准。安非他酮（32%，n=49）和舍曲林（26%，n=40）是最常见的禁忌药物。假阳性率为 9.2%：这项回顾性分析证实了人们的担忧，即某些药物可能会干扰 DAT-SPECT 成像结果，从而导致潜在的假阳性。这对临床医生如何解释服用这些药物的患者的 DAT-SPECT 成像以及是否应建议患者在扫描前停用这些药物都有影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurodegenerative Diseases 医学-临床神经学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Neurodegenerative Diseases'' is a bimonthly, multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer''s disease, Parkinson''s disease, amyotrophic lateral sclerosis, Huntington''s disease and related neurological and psychiatric disorders.